Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
Phase II Study: Hyperfractionated Pre-Op Chemo-Radiation for Locally Advanced Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may shrink the tumor so that it can be removed during surgery.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy and chemotherapy followed by surgery and combination chemotherapy in treating patients who have stage II or stage III rectal cancer.
研究概览
详细说明
OBJECTIVES: I. Determine the local recurrence rate, disease-free survival, and overall survival of patients with stage II or III rectal cancer treated with neoadjuvant radiotherapy and fluorouracil followed by surgical resection and adjuvant fluorouracil and leucovorin calcium. II. Determine the toxicity rate in patients treated with this regimen. III. Correlate failure-free survival with ultrasound-determined preoperative staging in patients treated with this regimen. IV. Determine the quality of life of patients treated with this regimen. V. Determine if toxicity due to treatment, daily stool frequency, sexual dysfunction, and disease-free survival correlates with quality of life parameters in patients treated with this regimen. VI. Correlate clinical selection criteria with ability to perform sphincter-sparing surgery in patients treated with this regimen. VII. Determine post-chemoradiotherapy pathological response, margin status, and lymph node status and correlate these factors with initial clinico-pathologic findings in patients treated with this regimen.
OUTLINE: Patients undergo pelvic radiotherapy once daily five days a week for 5 weeks followed by boost radiotherapy twice daily for 7 days. Patients also receive neoadjuvant fluorouracil IV continuously over days 1-4 and 36-40. Patients undergo surgical resection 4-6 weeks after completion of radiotherapy. At 4 weeks after surgery, patients receive adjuvant leucovorin calcium IV and fluorouracil IV once daily five days a week. Treatment continues every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at the completion of pelvic and boost radiotherapy, at 4 weeks after completion of chemoradiotherapy (prior to surgery), and then at 3, 6, and 12 months after completion of study therapy. Patients are followed every 3 months for 2 years, every 4 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 23-41 patients will be accrued for this study.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
New Jersey
-
Flemington、New Jersey、美国、08822
- Hunterdon Regional Cancer Center
-
Lakewood、New Jersey、美国、08701
- Kimball Medical Center
-
Mount Holly、New Jersey、美国、08060
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County
-
Red Bank、New Jersey、美国、07701
- Riverview Medical Center
-
Toms River、New Jersey、美国、08755
- Community Medical Center
-
Trenton、New Jersey、美国、08629
- St. Francis Medical Center
-
-
Pennsylvania
-
Altoona、Pennsylvania、美国、16602
- Bon Secours-Holy Family Health System
-
Drexel Hill、Pennsylvania、美国、19026
- Delaware County Memorial Hospital
-
Harrisburg、Pennsylvania、美国、17105-8700
- Pinnacle Health Hospitals
-
Johnstown、Pennsylvania、美国、15905
- Conemaugh Memorial Hospital
-
Langhorne、Pennsylvania、美国、19047
- Saint Mary Regional Center
-
Lansdale、Pennsylvania、美国、19446
- North Penn Hospital
-
Paoli、Pennsylvania、美国、19301-1792
- Paoli Memorial Hospital
-
Philadelphia、Pennsylvania、美国、19111
- Fox Chase Cancer Center
-
Pottstown、Pennsylvania、美国、19464
- Pottstown Memorial Regional Cancer Center
-
Reading、Pennsylvania、美国、19612-6052
- Reading Hospital and Medical Center
-
West Grove、Pennsylvania、美国、19390
- Southern Chester County Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the rectum
- Tumor extending through bowel wall (T3) OR
- Fixation to surrounding structures (T4) OR
- Nodal involvement by endorectal ultrasound (N1-2)
Tumor extending through bowel wall, but not fixed (T3) must be:
- At least 4 cm or at least 40% of bowel circumference OR
- Accompanied by nodal involvement
Evidence of transmural penetration confirmed by 2 of the following:
- CT scan
- Pelvic MRI
- Transrectal ultrasound
- Physical exam
- Proximal extent of tumor must not extend higher than 12 cm above dentate line and must be below pelvic peritoneal reflexion or sacral promontory
- Regional lymph node involvement allowed
- No distant metastases by CT scan of abdomen and pelvis or chest x-ray
PATIENT CHARACTERISTICS:
- Age: Over 18
- Performance status: ECOG 0-1
- Life expectancy: At least 2 years
Hematopoietic:
- Leukocyte count greater than 4,000/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin greater than 10 g/dL
Hepatic:
- SGOT and SGPT less than 1.5 times normal
- Bilirubin less than 1.5 mg/dL
- Renal: Creatinine less than 1.8 mg/dL
Other:
- Not pregnant or nursing
- Negative pregnancy test
- No other prior or concurrent malignancy within the past 5 years except inactive non-melanoma skin cancer or carcinoma in situ of the cervix
- No psychiatric condition that would preclude informed consent
- No other serious medical illness that would limit survival
PRIOR CONCURRENT THERAPY:
- Biologic therapy: Not specified
- Chemotherapy: No prior chemotherapy for rectal cancer
- Endocrine therapy: Not specified
- Radiotherapy: No prior radiotherapy for rectal cancer
- Surgery: No prior surgery for rectal cancer, except diagnostic biopsy
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Frequency of toxicity
大体时间：weekly during treatment
|
weekly during treatment
|
|
tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy
大体时间：during radiation therapy and chemotherapy
|
during radiation therapy and chemotherapy
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.